| Literature DB >> 29702593 |
Yasser H A Hussein1, Mohamed Youssry2.
Abstract
Polymeric micelles are potentially efficient in encapsulating and performing the controlled release of various hydrophobic drug molecules. Understanding the fundamental physicochemical properties behind drug⁻polymer systems in terms of interaction strength and compatibility, drug partition coefficient (preferential solubilization), micelle size, morphology, etc., encourages the formulation of polymeric nanocarriers with enhanced drug encapsulating capacity, prolonged circulation time, and stability in the human body. In this review, we systematically address some open issues which are considered to be obstacles inhibiting the commercial availability of polymer-based therapeutics, such as the enhancement of encapsulation capacity by finding better drug⁻polymer compatibility, the drug-release kinetics and mechanisms under chemical and mechanical conditions simulating to physiological conditions, and the role of preparation methods and solvents on the overall performance of micelles.Entities:
Keywords: biodegradable/biocompatible copolymers; diblock copolymers; drug encapsulation; physicochemical properties; polymeric micelles
Year: 2018 PMID: 29702593 PMCID: PMC5978065 DOI: 10.3390/ma11050688
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Schematic representation for the micellization of diblock copolymers and drug encapsulation in polymeric micelle. CMC: critical micelle concentration.
Rational design of an “ideal” polymeric micelle for cancer therapy taking into account all the biological requirements. Adapted with permission from [28].
| Requirement | Consequences in Polymeric Micelle Design |
|---|---|
| Protect drug from degradation | Encapsulation into the micellar core. |
| Intravenous injection | Sub-100 nm. |
| Obtain the desired micelle size | Adjust the physicochemical properties of the polymer with its constituents and apply an adequate preparation method. |
| Prevent opsonization | Coating with hydrophilic polymer (PEG). |
| Decrease the drug release rate | Adjust the core–drug compatibility (χ). |
| Control of biodistribution | Introduction of targeting moieties (antibodies, peptides, carbohydrates). |
| Control of pharmacokinetics and pharmacodynamics | All previous parameters. |
| Elimination | Use of biocompatible and biodegradable materials. |
Figure 2Itinerary of a drug carrier after intravenous administration. Adapted with permission from [13]. RES: reticuloendothelial system.
Factors affecting the performance-released properties of polymeric micelles as drug carriers. Adapted with permission from [29]. MW: molecular weight; C: concentration; HLB: hydrophilic-lipophilic balance; PDI: polydispersity index; δ, δ, δ: solubility parameters of hydrophilic, hydrophobic blocks, and drug, respectively; Tg: glass transition temperature; vm: the molar volume of the drug molecules; K: the dissociation rate; LE: loading efficiency; and RP: release profile.
| Factors | Performance Properties | ||||||
|---|---|---|---|---|---|---|---|
| Stability, | Size | Surface Properties, Hydrophilicity | Morphology | LE | RP | ||
|
| MW | ||||||
|
| |||||||
| HLB | |||||||
| PDI | |||||||
|
|
| ||||||
|
| |||||||
| Tg | |||||||
| Biodegr-adibility | |||||||
|
|
| ||||||
|
| |||||||
| Biocomp-atibility | |||||||
|
|
| ||||||
|
| |||||||
|
| |||||||
|
| |||||||
Comparative survey of some block copolymers, their characteristics, and their efficiency in encapsulating hydrophobic drugs (loading efficiency, LE%) using different preparation methods.
| Polymer | Core/Corona wt Ratio | Method | Size of Unloaded Micelles (nm) | Drug | Size of Loaded Micelles (nm) | LE% | Ref. |
|---|---|---|---|---|---|---|---|
| PEG5000-PCL5000 | 1.0 | Sonication | 69.0 | Saglopine | ND | 70 | [ |
| PEG2000-PCL1400 | 0.7 | 55.0 | ND | 66 | |||
| MPEG5000-PCL5000 | 1.0 | Cosolvent evaporation | 87.5 | CsA | 100 | 52.2 | [ |
| MPEG5000-PCL13000 | 2.6 | 78.7 | 98.6 | 63.8 | |||
| MPEG5000-PCL24000 | 4.8 | 99.8 | 102.3 | 49.5 | |||
| PEG2000-PCL2000 | 1.0 | Solvent displacement/sonication | 17.0 | Doxorubicin | 25.4 | 3.29 | [ |
| MPEG5000-PCL2500 | 0.5 | 29.7 | 22.9 | 3.10 | |||
| MPEG5000-PCL5000 | 1.0 | 41.0 | 37.3 | 4.03 | |||
| MPEG5000-PCL8500 | 1.7 | 56.9 | 84.0 | 4.09 | |||
| MPEG5000-PCL24700 | 4.9 | 86.3 | 104.9 | 4.30 | |||
| MPEG2000-PCL1200 | 0.6 | Cosolvent evaporation | 29.4 | Paclitaxel | 31.3 | 3.3 | [ |
| MPEG2000-PCL2700 | 1.4 | 37.3 | 42.6 | 13 | |||
| MPEG5000-PCL3800 | 0.7 | 71.8 | 65.3 | 23 | |||
| MPEG5000-PCL18000 | 3.6 | 97.7 | 91.9 | 38 | |||
| PEG5000-PCL4000 | 0.8 | Dialysis | ND | Ellipticine | 20 a | 75.9 a | [ |
| Dry down | ND | 76 a | 65.3 a | ||||
| PEG2000-PCL900 | 0.5 | Dialysis | ND | FK506 | 50 | 21 | [ |
| PEG1980-PCL1368 | 0.3 | Dialysis | ND | 17 | ND | 10 | [ |
| PEG1980-PCL2622 | 0.5 | 25 | 30 | 19 | |||
| PEG1980-PCL17328 | 3.4 | ND | ND | 90 | |||
| PEG2000-PCL2280 | 1.1 | Cosolvent evaporation | ND | Cabazitaxel | 28.8 | 99.3 | [ |
| PEG5000-PCL5000 | 1.0 | Cosolvent evaporation | ND | Cucurbitacin B | 73.3 | 30.2 | [ |
| PEG5000-PCL24000 | 4.8 | ND | 78.3 | 65.1 | |||
| PEG5000-PCL5000 | 1.0 | ND | Cucurbitacin I | 72.2 | 44.1 | ||
| PEG5000-PCL24000 | 4.8 | ND | 77.2 | 68.4 | |||
| PEG5000-PCL4790 | 1.0 | Dialysis | 62.5 | Paclitaxel | 69.2 | 24.7 | [ |
| PEG5000-PCL10000 | 2.0 | Cosolvent evaporation | ND | Dasatinib | 54.3 | 95.4 | [ |
| MPEG5333-PCL2638 | 0.5 | Dialysis | 54 | Indomethacin | ND | ND | [ |
| MPEG5333-PCL4984 | 0.9 | 77 | ND | ND | |||
| MPEG5333-PCL8034 | 1.5 | 114 | 120–165 b | 16.8–42.2 b | |||
| MPEG5333-PCL9068 | 1.7 | 130 | ND | ND | |||
| MPEG5000-PCL2166 | 0.4 | Emulsion-solvent evaporation | 45.3 | Indomethacin, Curcumin, Plumbagin, Paclitaxel, Etoposide | See Ref. [ | [ | |
| MPEG2000-PCL1320 | 0.7 | 22.3 | |||||
| MPEG2000-PCL852 | 0.4 | 14.7 | |||||
| MPEG750-PCL464 | 0.6 | 12.4 | |||||
| MPEG750-PCL323 | 0.4 | 13.5 | |||||
| MPEG750-PCL197 | 0.3 | 11.1 | |||||
| MPEG-PCL | Direct dissolution assisted by ultrasound | 27 | Honokiol | 31 c | 65.4 c | [ | |
| PEG5000-PDLLA4200 | 0.8 | Dialysis | ND | Ellipticine | 76 | 1.2 | [ |
| Dry down | ND | 106 | 6.2 | ||||
| PEG5000-PDLLA45000 | 9.0 | Emulsion-solvent evaporation | ND | Lidocaine | 203 | 17 | [ |
| MPEG2000-PDLLA2000 | 1.0 | Emulsion-solvent evaporation | ND | Paclitaxel | <50 nm | 25 | [ |
| MPEG2000-PDLLA1333 | 0.7 | ND | 25 | ||||
| MPEG5000-PDLLA2143 | 0.4 | ND | 10 | ||||
| PEG52000-PDLLA56000 | 1.1 | Dialysis | 33 | ND | ND | ND | [ |
| PEG91000-PDLLA56000 | 0.6 | 30 | ND | ND | |||
| PEG4100-PDLLA1200 | 0.3 | Dialysis | 154 | ND | ND | ND | [ |
| PEG6000-PDLLA3000 | 0.5 | 28.1 | ND | ND | |||
| PEG5700-PDLLA5400 | 1.0 | 33.5 | ND | ND | |||
| PEG6100-PDLLA7800 | 1.3 | 35.0 | ND | ND | |||
| PEG5000-PBCL4700 | 0.9 | Cosolvent evaporation | ND | Cucurbitacin B | 76.3 | 92.9 | [ |
| ND | Cucurbitacin B | 74.1 | 74.1 | ||||
| PEG5000-PBCL4470 | 0.9 | Dialysis | 64.3 | Paclitaxel | 61.0 | 36.4 | [ |
| PEG12000-PBLA5000 | 0.4 | Dialysis d | 19 | Indomethacin | 29 | 20.4 | [ |
| o/w emulsion | ND | 25 | 22.1 | ||||
| PEG12000-PBLA3000 | 0.3 | Dialysis | 20 | Amphotericin B | 25.8 | 27–30 e | [ |
| PEG-PBLA | Dialysis | >100 | KRN 5500 | [ | |||
| PEG12000-PBLA5000 | 0.4 | o/w emulsion | 19 | Doxorubicin | 37 | 65 | [ |
| MPEG2000-PVL1000 | 0.5 | Emulsion-solvent evaporation | ND | Paclitaxel | 200 | 37 | [ |
| MPEG2000-PVL2000 | 1.0 | ND | 31 | 92 | |||
| MPEG5000-PVL2600 | 0.5 | ND | 225 | 10 | |||
| MPEG5000-PVL4900 | 1.0 | ND | 138 | 3 | |||
a These values were taken at drug/polymer = 1/10. b These values depend on the drug/polymer weight ratio and the solvent used in the dialysis method. c The drug-loaded micelle size and loading efficiency at drug/micelle = 8/20. d Dialysis method was used to prepare unloaded micelles, and dialysis and o/w emulsion methods were used to prepare drug-loaded micelles. e The drug-loading efficiency ranges from 27 to 30%, depending on the drug/polymer ratio. ND = not determined.
Variation of the CMC of various block copolymers with the hydrophobic/hydrophilic ratio and hydrophobic length.
| Polymer | Core/Corona Ratio | CMC (mg/L) | Ref. |
|---|---|---|---|
| PEG5000-PCL5000 | 1.0 | 1.8 | [ |
| PEG5000-PCL13000 | 2.6 | 0.8 | |
| PEG5000-PCL24000 | 4.8 | 0.5 | |
| MPEG5000-PCL2166 | 0.4 | 4.5 | [ |
| MPEG2000-PCL852 | 0.4 | 21.0 | |
| MPEG750-PCL323 | 0.4 | 122.1 | |
| MPEG750-PCL464 | 0.6 | 71.5 | |
| PEG12000-PBLG8400 | 0.7 | 2.7 | [ |
| PEG12000-PBLG39800 | 3.3 | 2.2 | |
| PEG12000-PBLG91700 | 7.6 | 2.0 | |
| PEG5000-PBLA2381 | 0.5 | 10 | [ |
| PEG5000-PBLA4762 | 1.0 | 5 | |
| PEG12000-PBLA4762 | 0.4 | 10 | |
| PEG12000-PBLA5000 | 0.4 | 18 | [ |
| PEG6000-PDLLA3000 | 0.5 | 4.5 | [ |
| PEG6100-PDLLA7800 | 1.3 | 2.5 | |
| MPEG2000-PVL550 | 0.3 | 176 | [ |
| MPEG2000-PVL1000 | 0.5 | 80.4 | |
| MPEG2000-PVL2000 | 1.0 | 23.3 |
Common core-forming blocks and their characteristic crystallinity and glass transition temperatures (Tg).
| Polymer | Tg (°C) | State | Ref. |
|---|---|---|---|
| PCL | −60 | Semicrystalline | [ |
| PVL | −47 to −70 | Semicrystalline | [ |
| PDLLA | 34.5 | Amorphous | [ |
| PLGA | 40–60 | Amorphous | [ |
| PBLA | - | Amorphous | [ |
| PBLG | 50 | - | [ |
Figure 3Examples of the calculated Flory–Huggins interaction parameters (χ) for sets of hydrophobic blocks and drugs at 25 °C.
The calculated Flory–Huggins interaction parameters (χ) for different block copolymers and hydrophobic drug molecules at 25 °C.
| Drug | χPCL-drug | χPDLLA-drug | χPBLG-drug | χPVL-drug | χPLGA-drug |
|---|---|---|---|---|---|
| Fenofibrate | 0.002 | 5.380 | 0.563 | 2.222 | 3.983 |
| Curcumin | 6.563 | 0.017 | 3.047 | 0.969 | 0.216 |
| Cyclosporine A | 1.942 | 10.455 | 0.026 | 2.591 | 6.756 |
| Indomethacin | 2.872 | 0.422 | 0.823 | 0.030 | 0.108 |
| Paclitaxel | 8.908 | 0.470 | 3.069 | 0.363 | 0.033 |
| Camptothecin | 28.691 | 9.338 | 21.011 | 14.924 | 11.365 |